Night Ambulatory Monitoring Of Blood Pressure

Overview

To determine accuracy of nightly non occlusive blood pressure measurements by the non-occlusive CSEM Pulse Watch compared to a gold standard oscillometric device Spacelabs OnTrak Ambulatory Blood Pressure monitor, Spacelabs Healthcare, Washington, USA) internationally validated for the 24h ABPM in Patients.

Full Title of Study: “Night Ambulatory Monitoring Of Blood Pressure Clinical Study Protocol”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2019

Detailed Description

Elevated Blood Pressure (BP) is a chronic medical condition with a prevalence of about 45% in the middle-aged population.

The particular interest of this project is given to the diagnosis and treatment of so-called nocturnal hypertension. Unfortunately, current monitoring practice relies on the use of occlusive pneumatic cuffs inflated around the arm to assess BP. Based on oscillometric technique, occlusive cuffs perform intermittent BP measurements every 20 minutes, thus providing only a limited view of the BP regulation landscape. In addition, oscillometric measurement performs a full occlusion of the measured arm inducing awakening reactions, and leading to non-representative overestimated BP values. The non-occlusive measurement of BP is thus an unsolved problem of modern medicine.

The aim of the NAMBP (Night Ambulatory Monitoring of Blood Pressure) project is to develop, implement and test in clinical trials a first-ever non-occlusive BP sensor to be used during sleep.

A novel technology for the non-occlusive measurement of BP from photoplethysmographic (optical) signals, known as Pulse Wave Analysis (PWA), has been investigated for the past decade by the Centre Suisse d'Electronique et de Microtechnique (CSEM, Neuchâtel, Switzerland). The herein proposed system – the CSEM Pulse Watch – consists in a single sensor (watch-like device) attached at the wrist that measures photoplethysmographic waveforms induced by the pulsatility of the skin arteries of the wrist. These waveforms are then post-processed via PWA: The system will detect features in the measured waveforms that correlate, through the phenomenon of wave reflections, to the underlying BP of the patient.

Interventions

  • Device: CSEM Pulse Watch
    • Comparison of CSEM Pulse Watch with a gold standard oscillometric device Spacelabs OnTrak Ambulatory Blood Pressure monitor.

Arms, Groups and Cohorts

  • Other: Healthy and hypertensive subjects
    • Subjects will be enrolled to be monitored for 24 hours via: the non-occlusive CSEM Pulse Watch, and a gold standard oscillometric device (Spacelabs OnTrak Ambulatory Blood Pressure monitor, Spacelabs Healthcare, Washington, USA) internationally validated for the 24h ABPM.

Clinical Trial Outcome Measures

Primary Measures

  • Assessment of the accuracy
    • Time Frame: Day 0 for 24 hours
    • Continuous blood pressure measurement of the novel device will be compared to measurements assessed by a standard 24h blood pressure monitor at normal out of hospital conditions during night periods.

Secondary Measures

  • Assessment of the acceptability
    • Time Frame: Day 1
    • Acceptability of the novel blood pressure device in patients when used during 24 hours will be assessed by means of a questionnaire filled in by patients at day 1. The scale title is: Fragebogen. The minimum value is -1 and the maximum value is 10. The higher score means worse outcome.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients > 18y
  • Good understanding of written and oral German
  • Signed informed consent
  • Scheduled for 24h blood pressure exam

Exclusion Criteria

  • Patients with unhealthy mental state
  • Patients with an active implantable medical device (AIMD)
  • Arteriopathy of the upper limbs with/without stenosis
  • Severe congestive heart failure (LV-EF ≤25%)
  • Sever aortic-valve stenosis mean gradient >40mmHg, valve area <1cm2)
  • Congenital heart disease including aortic isthmus stenosis
  • Untreated heart rhythm disorders, heart rate at rest > 120/bpm
  • Severe untreated arterial hypertension (BPsyst > 180mmHg, BPdiast > 100mmHg)
  • Atrial fibrillation
  • Instable angina pectoris
  • Malcompliance concerning medication intake
  • Active alcohol or drug abuse
  • Pregnancy or lactation (women of childbearing age will be asked to performed urinary pregnancy test before the screening phase)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Hospital Inselspital, Berne
  • Collaborator
    • CSEM Centre Suisse d’Electronique et de Microtechnique SA – Recherche et Developpement
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Emrush Rexhaj, MD, Study Director, University Hospital Inselspital
  • Overall Contact(s)
    • Emrush Rexhaj, MD, +41316322111, emrush.rexhaj@insel.ch

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.